La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

IN8bio Crescita futura

Future criteri di controllo 0/6

Si prevede che IN8bio aumenterà i ricavi a una percentuale annua pari a 73.6%.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Biotechs crescita degli utili	34.8%
Tasso di crescita dei ricavi	73.6%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

MUN:6JH - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2024	N/A	N/A	N/A	N/A	2
12/31/2023	N/A	N/A	N/A	N/A	3
12/31/2022	N/A	N/A	N/A	N/A	3
9/30/2022	N/A	-27	-21	-18	N/A
6/30/2022	N/A	-21	-20	-19	N/A
3/31/2022	N/A	-18	-16	-16	N/A
12/31/2021	N/A	-15	-14	-14	N/A
9/30/2021	N/A	-12	-13	-13	N/A
6/30/2021	N/A	-11	-9	-9	N/A
3/31/2021	N/A	-11	-8	-8	N/A
12/31/2020	N/A	-10	-7	-7	N/A
9/30/2020	N/A	-9	-7	-7	N/A
6/30/2020	N/A	-8	-6	-6	N/A
3/31/2020	N/A	-6	-6	-5	N/A
12/31/2019	N/A	-6	-5	-5	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista 6JH è superiore al tasso di risparmio ( 0.03% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di 6JH cresceranno più velocemente del mercato German

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di 6JH cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che 6JH non avrà alcun fatturato il prossimo anno.

Ricavi ad alta crescita: Si prevede che 6JH non avrà alcun fatturato il prossimo anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di 6JH è previsto essere elevato tra 3 anni

IN8bio Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

IN8bio, Inc. announced that it expects to receive $12.405547 million in funding

IN8bio, Inc. Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio, Inc. Announces Updated Positive Clinical Data from Both of the Phase 1 Investigator-Sponsored Trials of INB-100 for Hematological Malignancies and INB-200 for GBM

IN8bio, Inc. Presents Positive Data Demonstrating Durable 1-Year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

IN8bio, Inc. Presents Progression-Free Survival Update from Phase 1 Study of INB-200 At 2024 American Society of Clinical Oncology Annual Meeting

In8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation At Asgct 2024

In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma

IN8bio, Inc., Annual General Meeting, Jun 12, 2024

IN8bio, Inc. Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

IN8bio, Inc. to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

IN8bio, Inc. announced that it has received $14.442298 million in funding from Bios Equity Partners LP

IN8bio, Inc. announced that it expects to receive $14.442298 million in funding

IN8bio, Inc. Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

IN8bio, Inc. Appoints Corinne Epperly to the Board of Directors

IN8bio, Inc.’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

IN8bio, Inc. Presents Biologic Correlative Data from the Inb-200 Phase 1 Trial in Newly Diagnosed Glioblastoma At the Society for Immunotherapy of Cancer's 38Th Annual Meeting

IN8bio, Inc. Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

IN8bio, Inc. Announces Presentations at the Society for Immunology of Cancer 38th Annual Meeting

IN8bio, Inc. Announces Updated Data from the Ongoing Phase 1 Clinical Trial of Inb-200 in Patients with Newly Diagnosed Glioblastoma Multiforme

IN8bio, Inc. Announces Positive Preclinical Data Underscoring the Potential of Its DeltEx Gamma-Delta T Cells to Target and Kill Ovarian Cancer

IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals

In8bio Announces New Data At Ash Showing 100% of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of Inb-100

IN8bio Announces FDA Clearance to Initiate A Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma

IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting

IN8bio, Inc. Appoints Michael R. Bishop to Its Scientific Advisory Board

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita